A battery of 10 SCLC cell lines were grown as 3D tumor spheroids and treated with eight small molecule inhibitors, two for each target (Table 1 and Table 2), in order to assess the efficacy of BET or Aurora Kinase inhibition in combination with EZH2 or PARP-1 inhibition on SCLC cells [35,36,37,38,39]. The gene discussed is PARP1; the disease is neoplasm.